Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

("Tissue Regenix or "The Group")

Tissue Regenix Group strengthens Board with Non-Executive appointment

York, 19 January 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix") or ("The Company") the regenerative medical devices company, is pleased to announce the appointment of Jonathan Glenn as a Non- Executive Director with immediate effect. 

Jonathan has been Chief Executive Officer at Consort Medical plc since December 2007, having originally joined the company in September 2006 as Chief Financial Officer. Prior to joining Consort Medical, he held a number of senior financial roles across the medical industry including Akubio Ltd 2005- 2006 and the Celltech Group plc 1998-2005. He has a broad range of commercial experience across the medical devices industry, particularly with regard to clinical trial management and the US market place. During his time with Celltech he was pivotal in the acquisitions of Chiroscience, Medeva and OGS.

John Samuel, Chairman of Tissue Regenix Group said:

"We are very pleased to announce the appointment of Jonathan to the board.

He has excellent experience in the medical devices market and we look forward to working with him, we believe his appointment will strengthen the Board as we move into our next stage of development.

This is an exciting time for Tissue Regenix following the successful commercialisation of our woundcare products in the US, and the encouraging progress from the orthopaedic clinical trials in the EU, as well as the ongoing work in our cardiac applications"

Further Information:

Full name: Jonathan M Glenn

Age: 47

CORPORATE BOARDS

Consort Medical - Member of the Board and Chief Executive Officer

FORMER CORPORATE BOARDS

Akubio Ltd. (03/2005 - 09/2006)

Oxford Glyosciences (04/1997 - 08/1998)

There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.

For more information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.